Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study

Journal of Neural Transmission

Volumn 103, Issue 6, 1996, Pages 699-715

  Przuntek, H ^a   Welzel, D ^b   Gerlach, M ^a,d   Blumner E ^e   Danielczyk, W ^f   Kaiser, H J ^c   Kraus, P H ^a   Letzel, H ^e   Riederer, P ^d   Uberla K ^g  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c Klinische Forschung   (Germany)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e Med Forschungsgesellschaft mbH   (Germany)

^f LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^g UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adverse effects; Bromocriptine; Early combination therapy; L DOPA; Levodopa; Long term treatment; Motor fluctuations; Parkinson's disease

Indexed keywords

BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; LEVODOPA;

ADULT; AGED; APPETITE DISORDER; ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DROWSINESS; DRUG COMBINATION; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; DYSPNEA; EUPHORIA; EYE DISEASE; FEMALE; HALLUCINATION; HEADACHE; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SLEEP DISORDER; SYNCOPE; VERTIGO; VOMITING; XEROSTOMIA;

AGED; ANTIPARKINSON AGENTS; BROMOCRIPTINE; DRUG COMBINATIONS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; INCIDENCE; LEVODOPA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOTOR NEURONS; PARKINSON DISEASE; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 10544247317     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01271230     Document Type: Article

References (42)

1. Armitage P, Berry G (1987) Statistical methods in medical research, 2nd edn. Blackwell, Oxford, p 205
2. Bakheit AMO, Henderson LM, Moore AP, Simpson JA, Thomas M (1990) Long-term double masked trial of early treatment with L-Dopa plus bromocriptine versus L-Dopa alone in Parkinson's disease. Eur Neurol 30: 108-111
3. Ben-Shlomo Y, Marmot MG (1995) Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 58: 293-299
4. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415-455
5. Boomsma F, Meerwaldt JD (1989) Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa. J Neurol 236: 223-230
6. Boyce S, Rupniak NMJ, Steventon MJ, Iversen SD (1990) Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys. Psychopharmacology 102: 21-27
7. Calne DB (1993) Treatment of Parkinson's disease. N Engl J Med 329: 1021-1027
8. Cox DR (1972) Regression models and life-tables. J R Stat Soc [B] 34: 187-220
9. Eichstädt H (1993) unpublished results
10. Falk RH, DeSilva RA, Lown B (1981) Reduction in vulnerability to ventricular fibrillation by bromocriptine, a dopamine agonist. Cardiovasc Res 15: 175-180
11. Fischer PA, Przuntek H, Majer M, Welzel D (1984) Kombinationsbehandlung früher Stadien des Parkinson-Syndroms mit Bromocriptin und Levodopa. Ergebnisse einer multizentrischen Studie. Dtsch Med Wochenschr 109: 1279-1283
12. Gawel M, Riopelle R, Libman I (1986) Bromocriptine in the treatment of Parkinson's disease. A double-blind study against L-Dopa/carbidopa. Adv Neurol 45: 535-538
13. Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 63: 793-807
14. Gerlach M, Riederer P, Youdim MBH (1995) Neuroprotective therapeutic strategies: comparison of experimental and clinical results. Biochem Pharmacol 50: 1-16
15. Götz ME, Künig G, Riederer P, Youdim MBH (1994) Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 63: 37-122
16. Graham WC, Sambrook MA, Crossman AR (1993) Differential effect of chronic dopaminergic treatment on dopamine-D(1) and dopamine-D(2) receptors in the monkey brain in MPTP-induced parkinsonism. Brain Res 602: 290-303
17. Hely MA, Morris JGL, Rail D, Reid WGJ, O'Sullivan DJ, Williamson PM, Genge S, Broe G (1989) The Sydney multicentre study of Parkinson's disease: a report on the first 3 years. J Neurol Neurosurg Psychiatry 52: 324-328
18. Hoehn HM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427-442
19. Kao A, Kriett JM, Tobler HG, Detloff BL, Pritzker MR, Benson DW Jr, Benditt DG (1984) Bromocriptine treatment of digitalis-induced ventricular tachyarrhythmias: studies in a canine model. JACC 4: 1188-1194
20. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
21. Lange KW, Rausch W-D, Gsell W, Naumann M, Oestreicher E, Riederer P (1994) Neuroprotection by dopamine agonists. J Neural Transm 43 [Suppl]: 183-201
22. LeWitt PA, Calne DB (1981) Recent advances in the treatment of Parkinson's disease: the role of bromocriptine. J Neural Transm 51: 175-184
23. Lieberman A, Goldstein M (1989) Dopamine agonists in advanced Parkinson's disease. In: Lieberman A, Lataste X (eds) Parkinson's disease. The role of dopamine agonists. The Parthenon Publishing Group, Carnforth, pp 35-53
24. Marsden CD, Parkes JD (1976) "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet i: 292-296
25. Muenter MO, Sharples NS, Tyce GM, Darley FL (1977) Patterns of dystonia ("I-D-I" and "D-I-D") in response to L-dopa therapy for Parkinson's disease. Mayo Clin Proc 52: 163-174
26. Nakanishi T, Mizuno Y, Goto I, Iwata M, Kanazawa I, Kowa H, Mannen T, Nishitani H, Ogawa N, Takahashi A, Tashiro K, Tohgi H, Yanagisawa N (1991) A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. The fourth interim report. Eur Neurol 31 [Suppl 1]: 3-16
27. Nilsson A, Hökfelt B (1978) Effect of the dopamine agonist bromocriptine on blood pressure, catecholamines and renin activity in acromegalics at rest, following exercise and during insulin induced hypoglycemia. Acta Endoc 88 [Suppl 216]: 83-96
28. Ogawa N, Tanaka K, Asanuma M, Kawai M, Masumizu T, Kohno M, Mori A (1994) Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res 657: 207-213
29. Olanow CW (1993) A radical hypothesis for neurodegeneration. TINS 16: 439-444
30. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SU, Mantel N, McPherson K, Peto J, Smith PG (1976) Design and analysis of randomized clinical trials requiring prolonged observations of each patient. I. Introduction and design. Br J Cancer 34: 585-612
31. Przuntek H, Welzel D, Blümner E, Danielczyk W, Letzel H, Kaiser H-J, Kraus PH, Riederer P, Schwarzmann D, Wolf H, Überla K (1992a) Bromocriptine lessens the incidence of mortality in L-Dopa-treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol 43: 357-363
32. Przuntek H, Welzel D, Schwarzmann D, Letzel H, Kraus P (1992b) Primary combination therapy of early Parkinson's disease. Eur Neurol 32 [Suppl 1]: 36-45
33. Rinne UK (1985) Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology 35: 1196-1198
34. Starke K, Majewski H, Ensinger H, Szabo B, Hedler L (1986) In vivo operation of prejunctional adrenoceptors in the peripheral sympathetic nervous system. In: Grobecker H, et al (eds) New aspects of the role of adrenoceptors in the cardiovascular system. Springer, Berlin Heidelberg New York Tokyo, pp 43-56
35. Tanaka M, Sotomatsu A, Yoshida T, Hirai S (1995) Inhibitory effects of bromocriptine on phospholipid peroxidation induced by DOPA and iron. Neurosci Lett 183: 116-119
36. Van Loon GR, Sole MJ, Bain J, Ruse JL (1979) Effects of bromocriptine on plasma catecholamines in normal men. Neuroendocrinology 28: 425-434
37. Webster DD (1968) Critical analysis of the disability in Parkinson's disease. Mod Treatment 5: 257-282
38. Weiner WJ, Factor SA, Sanchez-Ramos JR, Singer C, Sheldon C, Cornelius L, Ingenito A (1993) Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology 43: 21-27
39. Wooten GF (1988) Progress in understanding the pathophysiology of treatment-related fluctuations in Parkinson's disease. Ann Neurol 24: 363-365
40. Yoshikawa T, Minamiyama Y, Naito Y, Kondo M (1994) Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 62: 1034-1038
41. Ziegler MG, Lake CR, Williams AC, Teychenne PF, Shoulson I, Steinsland O (1979) Bromocriptine inhibits norepinephrine release. Clin Pharmacol Ther 25: 137-142
42. Zung WW (1965) A self-rating depression scale. Arch Gen Psychiatry 12: 63-70